Rambus R&D increased by 2.0% to $50.23M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.9%, from $42.62M to $50.23M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.47M | $35.59M | $36.26M | $39.82M | $39.54M | $39.30M | $40.12M | $41.90M | $41.58M | $37.37M | $35.99M | $37.36M | $40.53M | $41.30M | $43.70M | $42.62M | $46.33M | $49.51M | $49.25M | $50.23M |
| QoQ Change | — | +13.1% | +1.9% | +9.8% | -0.7% | -0.6% | +2.1% | +4.4% | -0.8% | -10.1% | -3.7% | +3.8% | +8.5% | +1.9% | +5.8% | -2.5% | +8.7% | +6.9% | -0.5% | +2.0% |
| YoY Change | — | — | — | — | +25.6% | +10.4% | +10.6% | +5.2% | +5.2% | -4.9% | -10.3% | -10.8% | -2.5% | +10.5% | +21.4% | +14.1% | +14.3% | +19.9% | +12.7% | +17.9% |